Intervention

Tislelizumab injection

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 2 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting0

Common conditions2

Lead sponsors shown2

Clinical trials

2 shown

SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）NCT07633873 · 2026-06-02

NOT_YET_RECRUITING

TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.NCT05718167 · 2023-02-01

UNKNOWN

Common conditions

Advanced Squamous Non-Small Cell Lung Carcinoma1 Non-Small Cell Lung Cancer1

Leading sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 1 CSPC Megalith Biopharmaceutical Co.,Ltd. 1

Trial status mix

NOT_YET_RECRUITING1

UNKNOWN1

Phase mix

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.